Use of a new cross-linked collagen membrane for the treatment of dehiscence-type defects at titanium implants: a prospective, randomized-controlled double-blinded clinical multicenter study

被引:82
|
作者
Becker, Juergen [1 ]
Al-Nawas, Bilal [2 ]
Klein, Marcus O. [2 ]
Schliephake, Hennig [3 ]
Terheyden, Hendrik [4 ]
Schwarz, Frank
机构
[1] Univ Dusseldorf, Dept Oral Surg, W Deutsch Kieferklin, D-40225 Dusseldorf, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Oral & Maxillofacial Surg, Hosp Mainz, Mainz, Germany
[3] Univ Gottingen, Dept Oral & Maxillofacial Surg, Gottingen, Germany
[4] Rotes Kreuz Krankenhaus, Dept Oral & Maxillofacial Surg, Kassel, Germany
关键词
bone regeneration; bone substitutes; clinical research; clinical trials; guided tissue regeneration; GUIDED BONE REGENERATION; DIFFERENT BARRIER MEMBRANES; NONRESORBABLE MEMBRANES; BIORESORBABLE BARRIER; DENTAL IMPLANTS; AUGMENTATION; AUTOGRAFTS;
D O I
10.1111/j.1600-0501.2008.01689.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The aim of the present randomized-controlled double-blinded clinical multicenter study was to assess the use of either a new cross-linked (VN) or a native collagen membrane (BG) for the treatment of dehiscence-type defects at titanium implants. A total of n=54 patients were recruited in four German university clinics. According to a parallel-groups design, dehiscence-type defects at titanium implants were filled with a natural bone mineral and randomly assigned to either VN or BG. Submerged sites were allowed to heal for 4 months. Primary (e.g., changes in defect length - Delta DL, quality of newly formed tissue [0-4] - TQ) and secondary parameters (e.g., membrane exposure, tissue conditions at dehisced sites) were consecutively recorded. Four patients were excluded due to an early wound infection (VN:3; BG:1), and one patient was lost during follow-up (VN). The mean Delta DL was 3.0 +/- 2.5 mm in the VN, and 1.94 +/- 2.13 mm in the BG group. The assessment of TQ revealed comparable mean values in both groups (VN: 3.05 +/- 1.66, BG: 3.46 +/- 1.48). A significant correlation between membrane exposure and inflammation of the adjacent soft tissue was observed in the VN group. In both groups, the mean DL and TQ values were not significantly different at either non-exposed or exposed implant sites. The results of the present study have indicated that VN supported bone regeneration on a level non-inferior to BG. However, in case of a premature membrane exposure, cross-linking might impair soft-tissue healing or may even cause wound infections. To cite this article:Becker J, Al-Nawas B, Klein MO, Schliephake H, Terheyden H, Schwarz F. Use of a new cross-linked collagen membrane for the treatment of dehiscence-type defects at titanium implants. A prospective randomized controlled double-blinded clinical multicenter study.Clin. Oral Impl. Res. 20, 2009; 742-749.doi: 10.1111/j.1600-0501.2008.01689.x.
引用
收藏
页码:742 / 749
页数:8
相关论文
共 29 条
  • [21] The safety and efficacy of botulinum toxin type A treatment in neurogenic detrusor overactivity and idiopathic overactive bladder: A systematic review and meta-analysis of prospective, randomized, double-blinded, placebo-controlled clinical trials
    Bijnens, A.
    Bijnens, L. J. M.
    Van Koeveringe, G. A.
    Vrijens, D. M. J.
    EUROPEAN UROLOGY, 2021, 79 : S28 - S28
  • [22] A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED phototherapy for skin rejuvenation: Clinical, profilometric, histologic, ultrastructural, and biochemical evaluations and comparison of three different treatment settings
    Lee, Seung Yoon
    Park, Ki-Ho
    Choi, Jung-Woo
    Kwon, Jung-Kyun
    Lee, Doo Rak
    Shin, Mi Sun
    Lee, Jee Sung
    You, Chung Eui
    Park, Mi Youn
    JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2007, 88 (01) : 51 - 67
  • [23] Efficacy and safety of the Chinese herbal medicine Bu-Shen-Huo-Xue granule for the treatment of coronary heart disease: study protocol for a multicenter, randomized, double-blinded, placebo-controlled clinical trial
    Liu, Lanchun
    Wang, Jie
    Li, Jun
    Li, Xiao
    Li, Rong
    Liu, Yongmei
    Yang, Guang
    Mao, Qiyuan
    Wang, Lin
    Yao, Zhengyang
    Wang, Yongcheng
    Zong, Shuli
    Liu, Chao
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [24] Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).
    Meng, Xue
    Zheng, Anping
    Wang, Jun
    Wang, Jianhua
    Li, Guang
    Zhu, Jun
    Ma, Hu
    Zhu, Xiaodong
    Shi, Anhui
    Dai, Chunhua
    Yan, Senxiang
    Wang, Buhai
    Qu, Zhongyu
    Han, Chun
    Sun, Xindong
    Ye, Ming
    Fan, Ruitai
    Huerxidan, Ni Yazi
    Wang, Xiaohong
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Multicenter, Double-Blinded, Randomized, Active-Sham Controlled Clinical Study Design to Assess the Safety and Effectiveness of a Novel High Frequency Electric Nerve Block System in the Treatment of Post-Amputation Pain QUEST
    Kapural, Leonardo
    Shah, Nemath Syed
    Fang, Zi-Ping
    Mekhail, Nagy
    JOURNAL OF PAIN RESEARCH, 2022, 15 : 1623 - 1631
  • [26] A multicenter randomized controlled clinical trial using a new resorbable non-cross-linked collagen membrane for guided bone regeneration at dehisced single implant sites: interim results of a bone augmentation procedure
    Wessing, Bastian
    Urban, Istvan
    Montero, Eduardo
    Zechner, Werner
    Hof, Markus
    Alandez Chamorro, Javier
    Alandez Martin, Nuria
    Polizzi, Giovanni
    Meloni, Silvio
    Sanz, Mariano
    CLINICAL ORAL IMPLANTS RESEARCH, 2017, 28 (11) : E218 - E226
  • [27] Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial
    Kampa, Naruepon
    Kaenkangploo, Duangdaun
    Jitpean, Supranee
    Srithunyarat, Thanikul
    Seesupa, Suvaluk
    Hoisang, Somphong
    Yongvanit, Karn
    Kamlangchai, Phanthit
    Tuchpramuk, Pongsatorn
    Lascelles, B. Duncan X.
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10
  • [28] Rationale and Design for the BLOCK-SAH Study (Pterygopalatine Fossa Block as an Opioid-Sparing Treatment for Acute Headache in Aneurysmal Subarachnoid Hemorrhage): A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial with a Sequential Parallel Comparison Design
    Busl, Katharina M.
    Smith, Cameron R.
    Troxel, Andrea B.
    Fava, Maurizio
    Illenberger, Nicholas
    Pop, Ralisa
    Yang, Wenqing
    Frota, Luciola Martins
    Gao, Hanzhi
    Shan, Guogen
    Hoh, Brian L.
    Maciel, Carolina B.
    NEUROCRITICAL CARE, 2025, 42 (01) : 290 - 300
  • [29] Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: a prospective, block-randomized, double-blinded, placebo-controlled clinical trial (vol 10, 1033188, 2023)
    Kampa, Naruepon
    Kaenkangploo, Duangdaun
    Jitpean, Supranee
    Srithunyarat, Thanikul
    Seesupa, Suvaluk
    Hoisang, Somphong
    Yongvanit, Karn
    Kamlangchai, Phanthit
    Tuchpramuk, Pongsatorn
    Lascelles, B. Duncan X.
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10